Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis J Denis

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 17, 2007
Europa Uomo: the European Prostate Cancer CoalitionTom Hudson, Louis J Denis
Cancer|June 23, 2009
Predictive modeling in prostate cancer. Conclusions and reflectionsLouis J Denis, Mary K Gospodarowicz
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 17, 2007
The prevention of prostate cancerKeith Griffiths, Domenico Prezioso, A Turkes, et al.
Acta Oncologica (Stockholm, Sweden)|May 25, 2011
Prostate cancer from the horizon of the patientLouis J Denis, Monique Roobol, Brigitte Dourcy-Belle-Rose
International Journal of Urology : Official Journal of the Japanese Urological Association|January 4, 2007
Estrogens and aspects of prostate diseaseDomenico Prezioso, Louis J Denis, Helmut Klocker, et al.
Investigational New Drugs|September 22, 2010
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabineLaura W Goff, Al B Benson, Patricia M LoRusso, et al.
Molecular Cancer Therapeutics|May 28, 2021
ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical ModelsRoger A Smith, David J Zammit, Nitin K Damle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumorsAlain C Mita, Louis J Denis, Eric K Rowinsky, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2009
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignanciesChia-Chi Lin, Muralidhar Beeram, Eric K Rowinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2015
Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer ScreeningAnssi Auvinen, Sue M Moss, Teuvo L J Tammela, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 17, 2007
Europa Uomo: the European Prostate Cancer CoalitionTom Hudson, Louis J Denis
Cancer|June 23, 2009
Predictive modeling in prostate cancer. Conclusions and reflectionsLouis J Denis, Mary K Gospodarowicz
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 17, 2007
The prevention of prostate cancerKeith Griffiths, Domenico Prezioso, A Turkes, et al.
Acta Oncologica (Stockholm, Sweden)|May 25, 2011
Prostate cancer from the horizon of the patientLouis J Denis, Monique Roobol, Brigitte Dourcy-Belle-Rose
International Journal of Urology : Official Journal of the Japanese Urological Association|January 4, 2007
Estrogens and aspects of prostate diseaseDomenico Prezioso, Louis J Denis, Helmut Klocker, et al.
Investigational New Drugs|September 22, 2010
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabineLaura W Goff, Al B Benson, Patricia M LoRusso, et al.
Molecular Cancer Therapeutics|May 28, 2021
ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical ModelsRoger A Smith, David J Zammit, Nitin K Damle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumorsAlain C Mita, Louis J Denis, Eric K Rowinsky, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2009
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignanciesChia-Chi Lin, Muralidhar Beeram, Eric K Rowinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2015
Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer ScreeningAnssi Auvinen, Sue M Moss, Teuvo L J Tammela, et al.
Pageof 2